TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with symptomatic FAI~* Clinical and radiographic evidence of FAI~* Patients able to provide consent to study participation~* Completion of 6 weeks of physical therapy program~Exclusion Criteria:~* Established Osteoarthritis (Kellgren-Lawrence \> 3)~* Minimum joint space \> 2 mm as measured on AP radiograph~* Hip dysplasia (center edge angle \< 20° on AP radiograph)~* Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes~* Patients with ongoing infection including HIV and Hepatitis~* Patient with history of osteomyelitis/septic arthritis~* Anticoagulation therapy~* Patients who are pregnant or breast feeding~* Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis~* Patients taking immunosuppressant medication~* Patients with abnormal hematology or serum chemistry lab results~* Patients receiving injection to treatment knee within 2 months of study enrollment~* BMI greater than 35 or less than 20

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- platelet-rich plasma (Type: EXPERIMENTAL): platelet-rich plasma injection into the head-neck junction of the hip joint
- Kenalog 10 mg/mL Injectable Suspension (Type: ACTIVE_COMPARATOR): corticosteroid injection into the head-neck junction of the hip joint

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Part A and B:~* Subject is male or female between 2 and 14 months of age~* The diagnosis of infantile spasms (IS)~* Subject has drug-resistant IS~Part C:~* Subject participated in EP0078 Part A and received 2 radiprodil treatment cycles~* Subject experienced a relapse of spasms during the down taper or within 5 half-lives (3 days) discontinuation of radiprodil treatment in Cycle 2 of Part A~* Electroencephalogram (EEG) on baseline Part C is compatible with the diagnosis of infantile spasms~Exclusion Criteria:~Part A and B:~* More than 6 months have passed since the diagnosis of Infantile Spasms (IS)~* Current treatment with cannabinoids~* Subject has hematocrit greater than 60~* Subject has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study~* Subject has a history or current condition predisposing to respiratory dysfunction~* Current treatment with felbamate~* Current treatment with perampanel~* Ketogenic diet~* Clinically significant lab abnormalities~* Clinically significant abnormality on ECG that, in the opinion of the Investigator, increases the safety risks of participating in the study~* Subject has a lethal or potentially lethal condition other than IS, with a significant risk of death before 18 months of age such as non-ketotic hyperglycinemia~* Body weight is below 4 kg~* Known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias~Part C:~* Subject experienced any acute tolerability issues in either treatment cycle in Part A which the investigator and the sponsor medical monitor consider a risk for further participation~* Subject met any withdrawal criteria in Part A~* Subject has experienced any adverse effects or developed any new medical conditions since enrollment in Part A which the investigator considers could significantly increase the safety risks of participating in Part C

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 14 Months
- Healthy Volunteers: f

Study Arms:
- Radiprodil (Type: EXPERIMENTAL): Each subject will enter an individualized dose titration schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)~* Has virally suppressed CHB:~HBV DNA \<LLOQ and serum HBsAg \>100 IU/mL~* Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening.~* Is not of childbearing potential or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study.~Main Exclusion Criteria:~* Is an employee of a contract research organization (CRO), vendor, or Sponsor involved with this study.~* Has known hepatocellular carcinoma or pancreaticobiliary disease.~* Neutropenia (defined by two confirmed values within screening period of \<1500/μL).~* Has Gilbert syndrome.~* Shows evidence of worsening liver function, defined as either a confirmed (two assessments at least 3 days apart) increase \>2 ULN ALT or AST or an increase of \>1.5 × first assessed value of TBL or associated with clinical signs or symptoms of liver impairment.~* Has known or suspected non-CHB liver disease~* History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices.~* Probable or possible F3 stage with a vibration controlled transient elastography (VCTE). Patients with normal baseline ALT and VCTE \>8.8 kPa are excluded. Patients with baseline ALT \>ULN (but \<2ULN per EC5) and who have VCTE \>10.5 kPa at baseline are excluded 11.~* Has known history of alcohol abuse or daily heavy alcohol consumption~* Has clinically relevant immunosuppression, including, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.~* Has used anti-HBV medications other than NAs within 90 days prior to screening.~* Has any of the following exclusionary laboratory results at screening:~  1. Estimated glomerular filtration rate \<60 mL/min/1.73 m2 (the Modification of Diet in Renal Disease formula).~ 2. Thyroid-stimulating hormone \>1.5× ULN or abnormal free triiodothyronine or free thyroxine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
- Control Arm (Type: PLACEBO_COMPARATOR): Control Arm: Placebo + NA daily (12 patients)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life and Acupuncture on Chronic Pain: A Randomized Study Before and After Performing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 17 - 75 years old,~* suffering from arthritis pains,~* migraine backaches,~* muscular spasms,~* pains in the neck, and in the knee~* duration of disease over 1 year~Exclusion Criteria:~* tacking pain relief~* pregnant women

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- accupuncture, (Type: EXPERIMENTAL): The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of XIAP Antisense for Advanced Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically proven diagnosis of advanced or metastatic cancer (including solid tumours and lymphoma)~* refractory to conventional treatment, or for which no conventional therapy exists with life expectancy of at least 12 weeks~* ECOG performance status of 0 or 1~* hematological and biochemical indices as specified within one week prior to treatment~Exclusion Criteria:~* known bleeding diathesis or concurrent treatment with anticoagulants~* primary brain tumours or brain metastases~* radiotherapy (except palliative), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas and mitomycin-C)~* all toxic manifestations of previous treatment must have resolved (excepting alopecia or certain Grade 1 toxicities)~* pregnant or lactating women~* major thoracic and/or abdominal surgery in the preceding 4 weeks~* high medical risks from non-malignant systemic disease including uncontrolled infection~* hepatitis B, C or Human Immunodeficiency Virus~* allergic history to antisense agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation to Assess the Clinical Performance of the LumbaCure® Intervention on Chronic Low Back Pain Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic non-specific LBP (without red flag)~* Patient did not increase, on a long-term basis, his/her regular physical activity in the past 2 months.~* LBP is the principal musculoskeletal condition~* Aged between 18 and 65 years old~* Able to read and understand questionnaires and communicate with the physiotherapist.~* Average Back Pain intensity over the last week above 2, assessed on Numerical Pain Rating Scale from 0 to 10 anchored with no pain at 0 and worst pain imaginable  at 10.~* ODI score \> 20~Exclusion Criteria:~* Suspected or confirmed serious pathology (i.e infection, fracture, cancer, inflammatory arthritis, ....)~* Radicular pain~* Radiculopathy~* Cognitive impairment that precludes participant from consenting, completing investigation questionnaires or complying with recommendations~* Previous spine surgery in the last 3 months~* Pregnant women~* body weight \> 120 kg~* Neurological disease~* Fibromyalgia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Test Intervention arm (Type: EXPERIMENTAL): The LumbaCure® is a robotic system which provide active, specific and controlled mobilization of the low back. The device is to be used by the Physiotherapist at the rehabilitation centre. The duration of a session for the patient is 15 minutes.~Patients follow a serie of 12 consecutive LumbaCure® sessions at a frequency of 3 sessions / week for 4 weeks.
- Control Intervention arm (Type: ACTIVE_COMPARATOR): A set of core stability exercises/active qualitative mobilization has been defined with principal investigator according to the standard of care at Investigator site. At each session, 5 exercises will be selected by the investigator depending on the evolution and pathology of the patient. Five minutes of warm-up will be performed before starting the exercises session.~The program will last 15 to 30 min depending on the time required for the patient to complete the prescribed exercises.~Patients follow a serie of 12 consecutive physical exercises sessions at a frequency of 3 sessions / week for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of a venous ulcer on the lower extremity for at least 12 weeks14 days~* Presence of lymphedema in the lower extremity for at least 14 days~Exclusion Criteria:~* Pregnant women or women of childbearing potential not on contraception~* Previous use of the pneumatic compression device~* Class IV congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomization Arm 1: (Type: OTHER): 70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
- Randomization Arm 2: (Type: OTHER): 70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
- Observational Arm 3 (Type: OTHER): 50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of the Heart Repair Technologies Mitral Bridge in Treating Mitral Valve Regurgitation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients moderate to severe, symptomatic functional (ischemic or dilated cardiomyopathies) mitral regurgitation or mitral regurgitation caused by dilation of the mitral annulus who qualify for mitral valve repair with cardiopulmonary bypass~* Mitral regurgitation must meet the following criteria:~* The primary regurgitant jet is central, originating from mal coaptation of anterior and posterior leaflets of the mitral valve.~* If a secondary jet is present, the jet must be considered clinically insignificant.~* Women of child-bearing potential have a negative pregnancy test~Exclusion Criteria:~* Evidence of severe mitral annular and leaflet calcification.~* Patient is hemodynamically unstable.~* Patient has hypertrophic cardiomyopathy and has systolic anterior motion of the leaflets.~* Patient requires emergency surgery.~* Patient has echocardiographic evidence of endocarditis or rheumatic heart disease.~* Transesophageal Echocardiogram (TEE) is contraindicated or cannot be performed intraoperatively for any reason.~* Patient has known chronic, dialysis-dependent renal failure.~* History of stroke, transient ischemic attack (TIA) or reversible ischemic neurological disease within the last three (3) months.~* History of gastrointestinal bleeding within the last three (3) months.~* History of hypersensitivity or allergy to aspirin~* History or hypersensitivity to clopidogrel (Plavix) or its congeners.~* Active or treated malignancies in the last twelve (12) months.~* Patient is participating in another clinical study for which follow-up is currently ongoing.~* Women of child-bearing age who have not had a negative pregnancy test.~* Patient with non-cardiac co-morbidities and life expectancy \< 1 year.~* Patient has a condition that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe hyponatremia (Na \< 130 mmol/L) or~* symptomatic hyponatremia - Na \< 135 mmol/L for at least six hours with Glasgow Coma Scale \< 15~Exclusion Criteria:~* Enrollment in the NMH high-risk spine protocol. These patients receive large amounts of fluids, have rapid changes in electrolytes, and are typically corrected in 48 hours~* Expected death from any cause~* Known sensitivity or allergy to conivaptan~* Renal failure (baseline creatinine \> 1.5 mg/dL)~* Clinical diagnosis of hypovolemia, or by central venous pressure (CVP) \< 5 mm Hg if a central venous catheter is in place~* Concomitant use of potent inhibitors of cytochrome P-450 isoenzyme 3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir). These agents are not commonly used in the Neuro-ICU~* Clinical diagnosis of liver failure or insufficiency~* Pregnancy (must be excluded before entry)~* Lack of informed consent from the patient or a legally authorized representative (LAR)~* Use of intra-arterial vasodilators (e.g. verapamil, nicardipine) within 24 hours (e.g. for vasospasm after SAH)~* Concern by the Neuro-ICU pharmacist of a drug-drug interaction that would meaningfully impact care (the Neuro-ICU pharmacist will review the medication regimen before recruitment)~* Patients with a diagnosis of diabetes insipidus or treated with vasopressin, since these patients are already treated for abnormal free water balance~* Patients with congestive heart failure, since this is an approved use of the drug (these patients are typically not cared for in the Neuro-ICU)~* Age\<18 years (these patients are not cared for at NMH)~* Inclusion declined by the attending physician or consulting study nephrologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Conivaptan in addition to usual care at the discretion of the attending medical staff
- 2 (Type: NO_INTERVENTION): Usual care by the attending physician staff

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: First Line Chemotherapy for Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inoperable locally advanced, recurrent, and/or metastatic adenocarcinoma of the stomach or gastro-esophageal junction~* Adult patients \>=18 years of age~* Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;~* At least have one measurable disease(according to RECIST)~* Adequate bone marrow,renal and liver function~Exclusion Criteria:~* Previous chemotherapy for advanced/metastatic disease~* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albumin-bounded paclitaxel plus S-1 (Type: EXPERIMENTAL): arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Impact of Patient Navigators on the Health Education and Quality of Life in Formerly Incarcerated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older~* English or Spanish speaking~* release from the correctional system within the previous 6 months~Exclusion Criteria:~* unable to provide informed consent~* report duration of incarceration of less than 5 days~* report history of incarceration more than 6 months ago

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patient Navigation (Type: EXPERIMENTAL): Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
- Treatment as Usual (Type: NO_INTERVENTION): Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues